SCHEMBL732578

SCHEMBL732578

COC(=O)c1ccc2c(c1)c(C)nn2-c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.57
HPGD P15428 3/20 0.57
ALDH1A1 P00352 3/20 0.57
POLB P06746 2/20 0.57
HSD17B10 Q99714 2/20 0.57
FGFR1 P11362 1/20 0.53
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
GFER P55789 1/20 0.47
HTT P42858 1/20 0.47
LMNA P02545 1/20 0.46
MAPK14 Q16539 1/20 0.45
SPR P35270 2/20 0.45
MAPT P10636 2/20 0.45
TP53 P04637 1/20 0.45
KHK P50053 1/20 0.44
KDM4A O75164 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30204949 0.88 KDM4E (0.44) KDM4EHPGDALDH1A1POLBHSD17B10
SCHEMBL30864300 0.88 KDM4E (0.44) KDM4EHPGDALDH1A1POLBHSD17B10
SCHEMBL31633025 0.87 KMT2A (0.47) KDM4EHPGDALDH1A1POLBHSD17B10
SCHEMBL730542 0.86 HTT (0.58) KDM4EHPGDALDH1A1POLBHSD17B10
SCHEMBL31633048 0.84 KMT2A (0.48) KDM4EPOLBFGFR1SMN1; SMN2LMNA
SCHEMBL31632785 0.83 SPR (0.48) KDM4EHPGDALDH1A1POLBHSD17B10
SCHEMBL16127813 0.81 GAA (0.52) HPGDALDH1A1POLBMAPTPKM
SCHEMBL10324622 0.81 SCN9A (0.44) KDM4EHPGDALDH1A1POLBHSD17B10
SCHEMBL18561359 0.79 ADORA2A (0.47) KDM4EHPGDALDH1A1HSD17B10FGFR1
SCHEMBL347794 0.77 TDP1 (0.46) KDM4EHPGDALDH1A1POLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 KDM4E 3445/4885HPGD 2417/4885ALDH1A1 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.